Hemispherx Biopharma Announces Collaboration with Millions Missing Canada

Hemispherx Biopharma Announces Collaboration with Millions Missing Canada to Bring Medication to Canadians for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Advocacy Organization to Work with Health Canada with the Goal to Gain Approval

PHILADELPHIA, Aug. 08, 2017 (GLOBE NEWSWIRE) — Hemispherx Biopharma (NYSE MKT:HEB) has announced that on Thursday, August 3, 2017 it participated in a meeting in Toronto, Canada with Canadian advocates for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The meeting was  lead by Millions Missing Canada and a Canadian physician representing Canadian patients with ME/CFS, in support of a collaborative effort to advance ME/CFS research and potential treatments in Canada. This joint effort, which includes Dr. Ian Hyams, a leading physician specializing in ME/CFS management is the next step  to bringing Ampligen® to Canadians suffering from the disease.

Read the full article here.

 

One comment on “Hemispherx Biopharma Announces Collaboration with Millions Missing Canada

  1. Stacey Roy says:

    THis is fantastic news! Please share with me how I can be kept up to date on this treatment and what the criteria is.

Comments are closed.